Approach to Janus kinase inhibition for juvenile dermatomyositis among Childhood Arthritis and Rheumatology Research Alliance (CARRA) and Paediatric Rheumatology European Society (PReS) providers
Authors' conclusion
Paediatric rheumatologists use JAKi off-label for refractory JDM. Most providers noted clinical improvement in their patients. Barriers to JAKi use include lack of clinical data and insurance coverage.
Study context
- Population
- CARRA and PReS members (paediatric rheumatology providers) invited by e-mail; approaches to janus kinase inhibition (JAKi) for JDM18% response
- Participants
- 229 participants
- Outcome
- Use of JAKi for JDM among respondents
Methodological detailsinternational survey, electronic survey
- International survey
- Electronic survey
Main finding
As reported in the abstract
Respondents who had used JAKi (for over 450 patients with JDM)
150
Among users, noted clinical improvement in most or all patients
77%
Among users, reported side effects
17%
Observational data: associations, not effects.
Safety
Side effects reported by JAKi users
- Users reporting side effects
- 17%
Original publication
Approach to Janus kinase inhibition for juvenile dermatomyositis among CARRA and PReS providers. Rheumatology (Oxford). Published 10 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →